Inclusion Criteria:

- Patients with proven de novo or therapy-related MDS / CMML (WBC <13 GPT/l)according
to FAB and risk profile according to IPSS: intermediate II- risk or high-risk or
intermediate I with high-risk cytogenetic (according to IPSS, taking into account
that IPSS, however, was not validated for t- MDS), patients with secondary AML
(according to WHO) and blasts ≤ 30 % (= RAEB-t according to FAB)

- Previously untreated or maximal 1 cycle of 5-azacytidine (Vidaza®)

- Male or Female; Age 55 - 70 years

- Understand and voluntarily sign an informed consent form

- ECOG performance status of ≤ 2 at study entry

- Adequate renal and liver function: creatinine and bilirubin < 3 x the upper limit of
normal

- Sufficient cardiac function (ejection fraction > 30 %)

Exclusion Criteria:

- Blasts > 30 % in bone marrow at time of diagnosis

- Central nervous involvement

- Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

- Total bilirubin, SGPT or SGOT ≥ 3 times upper the normal level

- Left ventricular ejection fraction < 30 %

- Creatinine clearance < 30 ml/min

- DLCO < 35 % and/or receiving supplementary continuous oxygen

- Pregnant or breastfeeding female subject

- Patients with a life-expectancy of less than six months because of another
debilitating disease

- Serious psychiatric or psychological disorders

- Uncontrolled invasive fungal infection at time of registration

- Known positive for HIV or acute infectious hepatitis, type A, B or C

- Participation in another study with ongoing use of unlicensed investigational product
from 28 days before study enrollment until the end of the study